The U.S. FDA approved Eli Lilly's drug, tirzepatide, for weight loss under the brand name Zepbound

  • Zepbound will be available in the U.S. by the end of the year at a list price of $1,059.87.
  • Lilly’s drug was approved for use by adults with a BMI of at least 30, or a BMI of 27 or more with another weight-related health issue.
  • Lilly is launching a commercial savings card program to make Zepbound more affordable for patients.
  • Eli Lilly shares have soared 67% in 2023 based on anticipation of the drug’s approval.
  • The approval could support up to 10 competing weight-loss products with annual sales reaching $100 billion within a decade.
  • Zepbound’s most common side effects include nausea, diarrhea, hair loss, and gastroesophageal reflux disease.